Results 71 to 80 of about 2,036 (191)

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea

Human Vaccines & Immunotherapeutics
The current standard-of-care prophylaxis for respiratory syncytial virus (RSV) is primarily administered to high-risk infant populations. We conducted a cost-effectiveness analysis to determine the economically justifiable price of nirsevimab compared ...
Hyun Jin Han, Semin Jang, Ryu Dahye, Haeseon Lee, Jiyeon Lee, Eun Jin Bae, Samira Soudani, Hae Sun Suh   +7 more
doaj   +1 more source

Sociodemographic Characteristics of Infants Receiving Nirsevimab

JAMA Network Open
This cohort study investigates inequalities by sociodemographic group in the receipt of nirsevimab immunization by infants in France from 2023 to 2024.
Boutin, Salomé, Bertrand, Marion, Cohen, Jérémie F., Zureik, Mahmoud, Chalumeau, Martin, Jabagi, Marie-Joëlle   +5 more
openaire   +2 more sources

Long‐acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention

Pediatric Investigation, Volume 10, Issue 4, Page 293-299, August 2026.
Ran Wang, Bahaa Abu‐Raya, Hala Obeid, Zhengde Xie   +3 more
wiley   +1 more source

Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany

Influenza and Other Respiratory Viruses, Volume 20, Issue 6, June 2026.
ABSTRACT After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%–70% in secondary care. Inpatients under 6 months showed the greatest reduction.
Wei Cai, Isabelle Maronde, Sophie Köndgen, Barbara Biere, Silke Buda, Brunhilde Schweiger, Doreen Staat, Walter Haas, Ekkehard Schuler, Virologic SARI Surveillance Study Group, Thorsten Wolff, Ralf Dürrwald, Djin‐Ye Oh, Kristin Tolksdorf, Janine Reiche   +14 more
wiley   +1 more source

Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

The study was funded by the Institute of Health Carlos III (on its own budget) which, at the institutional level, had no role in the study design, data collection, analysis or interpretation.Using real-life data from Spain between October 2023 and March ...
Nuñez, Olivier, Pastor-Barriuso, Roberto, Monge Corella, Susana, Nirsevimab Effectiveness Study Collaborators, Jarrin Vera, Inmaculada   +4 more
core   +1 more source

Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023–2024 Season in Andalusia, Spain (NIRSEGRAND)

Vaccines
Background: Nirsevimab was indicated in a population level for all infants < 6 months during the 2023–2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for
David Moreno-Pérez, Aleksandra Korobova, Francisco de Borja Croche-Santander, Ana Cordón-Martínez, Olga Díaz-Morales, Leticia Martínez-Campos, Elena Pérez-González, María del Carmen Martínez-Padilla, Juan Luis Santos-Pérez, Jaime Brioso-Galiana, María Isabel Sánchez-Códez, Jorge Del Diego-Salas, Mario Rivera-Izquierdo, Nicola Lorusso   +13 more
doaj   +1 more source

Impact of the 2025 New South Wales Respiratory Syncytial Virus Prevention Program on Infant Notifications and Hospitalisations: A Population‐Based Analysis

Medical Journal of Australia, Volume 224, Issue 6, June 2026.
ABSTRACT The 2025 NSW RSV Prevention Program, which achieved an estimated coverage of 63% maternal vaccination and 18% for infant immunisation, led to more than 40% reduction in RSV notifications and hospitalisations among infants aged younger than 6 months.
Janaki Amin, Sally L. Ellis, Christopher Lambeth, Jessica Gugusheff, Christine Selvey   +4 more
wiley   +1 more source

Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)

Viruses
Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the
Paolo Manzoni, Matteo Riccò, Chryssoula Tzialla, Graziano Barera, Paolo Del Barba, Simona De Franco, Guido Pellegrini, Enrico Crapanzano, Giangiacomo Nicolini, Andrea Alba, Stefano Fiocchi, Mauro Vivalda, Giulia Natta, Alessandra Casati, Mariano Manzionna, Simone Rugolotto, Laura Saggioro, Simona Pesce, Maria Scavone, Antonietta Distilo, Vincenza Roseto, Antonino Di Toro, Luca Pierri, Gianfranco Scarpelli, Elvira Bonanno, Lidia Decembrino, Enrico Felici, Camilla Selvatico, Valentina Saracco, Francesco Morrone, Claudio Costantino, Cecilia Nobili, Mario Giuffrè   +32 more
doaj   +1 more source

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods A cohort model was ...
Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W. Law, Diana Mendes   +9 more
doaj   +1 more source

Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. [PDF]

Front Pediatr
Introduction: The 2024–2025 winter season was the first in which Nirsevimab was adopted as universal prophylaxis for bronchiolitis in Friuli Venezia Giulia, a region in the northeastern Italy.
Tonetto S, Cason C, Fasiolo E, Dal Cin M, Cozzi G, Giangreco M, Zappetti C, Nider S, Amaddeo A, Comar M, Travan L.   +10 more
europepmc   +2 more sources